1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Gland Pharma Ltd.

Gland Pharma Ltd.

2,858.70
INR
-65.60
(-2.24%)
70.41EPS
35.09P/E
407.78BMarket Cap
Nov 06Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
96.77
122.07
157.5
216.58
267.08
218.17
342.54
338.93
388.63
409.32
Basic EPS, GAAP
19.66
27.67
47.33
63.07
73.81
47.44
46.9
42.4
62.35
70.44
Free Cash Flow per Basic Share
7.16
3.03
31.01
23.8
16.37
8.56
36.34
31.6
32.59
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
20
18
- -
Book Value per Share
147.62
175.28
223.31
360.85
435.64
483.22
529.65
555.41
628.68
- -
Tangible Book Value per Share
147.62
175.28
223.31
360.85
434.87
482.51
508.13
533.93
604.25
- -
Basic Weighted Avg Shares
163
163
163
158
164
165
165
165
165
165
Sales/Revenue/Turnover
15,801
19,931
25,718
34,236
43,841
35,919
56,417
55,836
64,029
67,440
Operating Margin (%)
29
30.8
33.54
35.16
31.94
24.22
17.66
15.94
18.84
20.41
Depreciation Expense
784
821
946
988
1,103
1,467
3,446
3,779
4,237
4,286
Net Income, GAAP
3,211
4,519
7,729
9,970
12,117
7,810
7,725
6,985
10,273
11,606
Effective Tax Rate (%)
35.98
34.16
22.16
25.31
25.14
25.94
31.79
34.27
29.86
28.17
Profit Margin (%)
20.32
22.67
30.05
29.12
27.64
21.74
13.69
12.51
16.04
17.21
Working Capital
13,530
18,247
24,873
46,111
52,701
61,717
42,468
52,181
59,184
- -
LT Debt
66
60
50
47
45
37
1,412
1,072
932
- -
Total Equity
24,104
28,620
36,462
59,032
71,576
79,587
87,238
91,507
103,580
- -
Return on Invested Capital (%)
- -
15
20.92
18.74
15.99
8.07
7.94
6.28
8.2
- -
Return on Capital (%)
- -
17.16
23.85
20.9
18.58
10.39
9.23
7.79
10.43
- -
Return on Common Equity (%)
- -
17.14
23.75
20.88
18.55
10.33
9.26
7.82
10.53
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,904
- -
LT Borrowings
- -
699
- -
LT Finance Leases
- -
233
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
165
165
165
Market Capitalization
283,760
279,641
407,781

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
75,268
- -
Cash, Cash Equivalents & STI
- -
34,328
- -
Accounts Receivable, Net
- -
18,914
- -
Inventories
- -
17,439
- -
Total Current Liabilities
- -
16,084
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,904
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.03%
13.19%
Free Cash Flow
- -
47.78%
3.15%
Net Income, GAAP
- -
4.48%
47.07%
Sales/Revenue/Turnover
- -
16.14%
14.67%
Total Cash Common Dividend
- -
- -
-10%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
14,017
14,058
13,841
14,249
55,836
2026
15,056
- -
16,954
17,428
64,029
2027
18,003
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
8.73
9.93
12.42
11.32
42.4
2026
13.08
- -
15.87
22.26
62.35
2027
19.23
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
20
2026
- -
- -
- -
- -
18
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Shyamakant Giri
Full Time Employees
4,332
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No. 11 & 84, TSIIC Phase: IV Sangareddy TS India 502307
IPO Date
Nov 20, 2020
Website
glandpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Gland Pharma Limited manufactures and markets complex generic injectable pharmaceuticals. The company produces sterile injectables including oncology and ophthalmics; complex injectables such as NCE-1s, First-to-File products and 505(b)(2) filings; formulations delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and specialized products like peptides, long-acting injectables, suspensions and hormonal therapies, with new delivery systems including pens and cartridges in development. It supplies products across therapeutic categories encompassing anti-infectives, anti-neoplastics, blood-related therapies, cardiac, gastrointestinal, hormones, neuro/CNS, pain and analgesics, respiratory, and vitamins, minerals and nutrients; and provides contract development and manufacturing organization (CDMO) services. Gland Pharma operates in over 60 countries including the United States, Europe, Canada, Australia, New Zealand, India and other markets. Founded in 1978 and headquartered in Hyderabad, India, the company functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd. Recent developments include a 250% expansion of GLP-1/cartridge production capacity from 40 million to 140 million units to address demand for diabetes and obesity treatments; launch of its first partnered GLP-1 product, Liraglutide; new product launches comprising four molecules in Q4 FY25; leadership changes with Srinivas Sadu appointed Executive Chairman and Shyamakant Giri as Chief Executive Officer in January 2025, alongside Satnam Singh Loomba joining as Chief Operating Officer in May 2024; and targeted annual revenue growth of 14-15% supported by expansions and a strengthened complex injectables pipeline.